As DETAGEN Genetic Diagnosis Research and Application Center;

Our journey; It started in 2008 in Kayseri.

In 2010, Detagen took the tender for the Genetic Laboratory of Malatya-Inönü University Medical Faculty Hospital and started to serve in the field of Genetic Laboratory in Public Hospitals. Afterwards, it rapidly increased its service area nationally.

As of 2010, Detagen started to make new investments in the field of genetics laboratory in order to maintain its momentum in the sector. In 2015, various protocols were signed with Erciyes University and TUBITAK Marmara Research Center to produce advanced R&D projects.

At the end of 2019, Detagen restructured and first established a R&D and production Center within Erciyes Technopark. In this center he established, he carries out various R&D and production activities with a PhD Doctor, two engineers, seven biologists/molecular biologists, and three technicians.

In January 2020, before the COVID-19 epidemic, the vaccine supply and production deficit of our country was noticed, and Detagen, with 100% capital, established Detavax Vaccine Research Inc. firm was established. With the establishment of Detavax, our R&D investments got stronger.

In 2021, considering the needs, Pathology-Cytology Laboratory and Microbiology Laboratory were established.

As of April 11, 2022, Detagen has two M.D. Prof, three M.D. Laboratory services are provided in the provinces of Kayseri, Samsun, Erzurum, Şanlıurfa, Konya and Isparta, with a total employment of 100 personnel, including Specialists, one M.D., one PhD, five Engineers, who are experts in their fields and graduate and postgraduate degrees.

Detagen Inc. has managed to increase its turnover in recent years by more than 100% with its investments. These achievements of Detagen have made its name frequently mentioned in national and international media. This rise achieved by Detagen has enabled some important international companies to become partners in Turkey. After the agreement with Biontech, "DETAGEN US CORP." in March 2022. A new company was established in New Jersey, USA.